FeesSafety
Pluang+

House of Doge acquires McQueen Labs to expand into $51B tokenized asset market with new yield vaults

Company Fundamentals
23 Oct 2026
GlobeNewsWire
View Source
Bullish
House of Doge acquires McQueen Labs to expand into $51B tokenized asset market with new yield vaults

House of Doge Inc. announced the acquisition of McQueen Labs' tokenization platform and credit assets, accelerating its entry into the $51 billion tokenized real-world asset market. This move supports House of Doge's plans to launch tokenized yield vaults, which use real-world credit assets on blockchain to generate income. The acquisition also brings leadership changes, with McQueen Labs' CEO Curt Hopkins appointed interim CEO and CFO of House of Doge. The company plans a corporate rebrand, stock reverse split, and further strategic initiatives to expand its digital finance offerings.

House of Doge's expansion into tokenized yield vaults is notable. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 23, 2026 19:12 WIB: Out of 142 priced US Financial stocks, 38 rose and 96 fell. Barclays PLC (BCS) traded at USD 21.66 with 0% Sell / 100% Buy order activity and a typical hold time of 63 days. American Express Co (AXP) was priced at USD 319.87 with 97% Sell / 3% Buy order activity and a typical hold time of 124 days. Affirm Holdings Inc (AFRM) closed at USD 71.29 with a typical hold time of 21 days.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App